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Abstract
Aim The purpose of this study is to report a case of endoge-
nous endopthalmitis caused by Scedosporium apiospermum
with a favorable outcome and review previously reported
cases, their treatment regimens and outcomes.
Methods An 83-year-old man with diabetes mellitus, no
other immunocompromising risk factors, and a history of
S. apiospermum endopthalmitis in the left eye developed
endopthalmitis in the right eye. Within 72 h of presentation,
he was treated with a pars plana vitrectomy and intravitreal
voriconozole.
Results Vitreous cultures confirmed S. apiospermum. The
patient responded to treatment, with a favorable outcome
and full recovery of vision.
Conclusions Recognition of S. apiospermum endopthalmitis
and appropriate early intervention with pars plana vitrectomy
and intravitreal voriconozole can lead to a favorable outcome
with restoration of visual acuity.
Keywords Endogenous endopthalmitis . Scedosporium
apiospermum
Introduction
Scedosporium apiospermum is an opportunistic fungus that
can affect the eye, presenting as keratitis, chorioretinitis, or
endophthalmitis, often with devastating consequences [1].
Disseminated life-threatening disease and endogenous
endophthalmitis are generally seen in immunocompromised
patients; however, immunocompetent individuals can also
be affected with exogenous endophthalmitis from trauma.
This species of Scedosporium, the anamorph (asexual
state) of Pseudallescheria boydii, is a ubiquitous filamentous
fungus, found in soil, sewage, and polluted water [1]. The
subclassification of this genetically heterogeneous species
makes medical literature confusing. Synomorphs of S. apio-
spermum includeMonosporium apiospermum,Monosporium
sclerotiale, Indiella americana, Acremoniella lutzi, and Poly-
cytella hominis [1]. In addition, the number of cases may be
underreported or misdiagnosed because it is clinically indis-
tinguishable from “the great imitator” and more commonly
occurring fungus, Asperigillus fumigatus [2, 3].
Although uncommon, S. apiospermum endophthalmitis
has been reported in the literature, with nine cases prior to
2005 reviewed by Larocco et al. [4–17], all with poor out-
comes. We review additional reported cases of endogenous
S. apiospermum endopthalmitis, including comorbidities,
treatment modality, and final outcomes (Table 1). Further-
more, we report a unique case of our own that was detected
early and treated aggressively, leading to a good outcome.
Case report
An 83-year-old monocular male presented with complaints
of new floaters in his right eye. His visual acuity was
counting fingers, intraocular pressure was 8 mmHg with 3+
cells in his anterior chamber, and a dense vitritis. Ultrasound
confirmed vitritis with an attached retina. The patient was seen
by a referring ophthalmologist the day before with similar
complaints of floaters with visual acuity of 20/40 due to
nuclear sclerosis.
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The patient had been no light perception in his left eye for
over a year due to endogeneous endophthalmitis from a
fungal lung lesion. At that time, both vitreous and lung
biopsies grew out S. apiospermum. Other than diabetes, a
thorough infectious disease work-up revealed no other
immunocompromising risk factors. The lung lesions were
unchanged after a course of treatment, and the patient’s
family did not want further work-up such as a re-biopsy
due to the patient’s age. The patient was prescribed a main-
tenance dose of voriconazole 200 mg PO QD, but he was
noncompliant and stopped taking his medicine.
At the time of presentation to our clinic, the patient had
symptoms in his right eye for less than 24 h. An intravitreal
biopsy was performed in conjunction with intravitreal vor-
iconazole (100 μg/0.1 ml). Vitreous biopsy at this time grew
out S. aspiospermum. The patient was also started on intra-
venous voriconazole. After 48 h with no improvement, the
patient was brought to the operating room for a 23-gauge
pars plana vitrectomy and repeat intravitreal voriconazole
(100 μg/0.1 ml) injection. There were no intraretinal lesions
seen at the time of surgery, although the view was hazy. The
patient did not receive any intravitreal or oral steroids. His
inflammation subsided slowly over the course of 3 weeks
with moxifloxacin and prednisolone acetate eye drops. One
month after presentation, his visual acuity returned to 20/40.
Discussion
S. apiospermum endophthalmitis presents with an aggressive
clinical course, oftentimes requiring enucleation. Treatment is
particularly challenging due to resistance to many antifungal
agents. Here, we report a case of endogenous S. apiospermum
endopthalmitis in a diabetic patient that responded favorably
to voriconazole with full restoration of visual acuity. To our
knowledge, this is the third reported case of successful treat-
ment outcome for endogenous endophthalmitis due to this
fungal species [5, 11]. Our case is unique in that voriconazole
combined with early surgical intervention led to a favorable
outcome.
Two cases of successful treatment outcomes for S. apio-
spermum endopthalmitis have previously been described. In
2007, Shankar et al. reported a case a case of endogenous
endophthalmitis from an unknown source in a 61-year-old
man with diabetes mellitus (DM). Anterior chamber biopsy
was positive for S. apiospermum and the patient was treated
with intravitreal amphotericin B and voriconazole with resto-
ration of vision [5].
Two years later, another case of S. apiospermum endoph-
thalmitis with a good outcome was published by Ikewaki et al.
They described a 58-year-old man with DM who developed
exogenous endopthalmitis following sub-Tenon’s injection
with triamcinolone acetonide for treatment of macular edema.
The patient was not diagnosed or treated until 5 months after
the sub-Tenon’s injection, when a periocular abscess was
drained with cultures revealing S. apiospermum. By this time,
extensive vitritis with opacities, pale optic disc, periphlebitis,
serous detachment of the macula, retinal hemorrhages, and
a whitish subretinal peripheral mass were seen. Follow-
ing a vitrectomy and irrigation with voriconazole, vision
was restored [11].
To date, a few over 20 cases of endogenous endopthalmitis
from S. apiospermum have been reported in the literature
(reviewed in Larocco et al. and Table 1). The collection of
cases, with a large proportion of systemically ill patients
having a wide range of presentations, emphasizes the need
to have adequate biopsy results. They also point out the
importance of working collaboratively with an infectious dis-
ease and internal medicine team. Various antifungal agents
have been administered intravitreously for treating fungal
endophthalmitis. The most common agent, amphotericin B,
is associated with retinal toxicity and resistance has emerged
[15, 18]. Amphotericin B is generally ineffective against S.
apiospermum and voriconazole, the second-generation deriv-
ative of fluconazole, is accepted as the treatment of choice for
this pathogen. It is a broad-spectrum antifungal agent with
high bioavailability, quick onset of action, and good ocular
penetration [15].
The investigation of the pharmacokinetics of voricona-
zole indicates that the MIC90 (minimum inhibitory concen-
trations at which 90% of isolates of S. apiospermum are
inhibited) can be attained in the vitreous and aqueous after
oral administration [15, 19]. Oral dosing is 200 mg BID
with or without a loading dose [15]. Alternatively, it can be
given twice a day IV with a loading dose of 6 mg/kg Q12
hours for 1 day, followed by 4 mg/kg BID. While animals
studies report a intravitreal voriconazole dose of 100 μg to
be effective and safe [20], 200 μg intravitreal injection has
been used successfully in humans [15].
Conclusion
In summary, this is rare a case of endogenous fungal
endophthalmitis due to S. apiospermum in which a history
of prior infection in the other eye allowed appropriate early
intervention, both pharmacologic and surgical, leading to a
successful outcome. The patient was treated aggressively
with intravitreal voriconazole, systemic voriconazole, and
pars plana vitrectomy leading to a favorable outcome. Thus,
it is reasonable to initiate early treatment with voriconazole
when fungal endopthalmitis is suspected even prior to obtain-
ing definitive culture results.
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